 TEL AVIV, Israel, Oct. 30, 2020 PRNewswire -- BioLineRx Ltd. NASDAQ: BLRX TASE: BLRX, a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell... 